# Imagen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/imagen

- Industry: Software
- Headquarters: Cambridge, UK
- Website: www.imagenevp.com
- Total disclosed funding: $17M
- Latest round: Series B (Jan 3, 2019)
- Investors on record: 3

## About

Imagen Ltd is a biotechnology company specializing in genome data analysis and biopharmaceutical development, providing advanced solutions that facilitate drug discovery and enhance personalized medicine strategies.Founded in 1991 in Cambridge, UK, Imagen Ltd focuses on genomics and biopharmaceutical development. The company has evolved its strategies while engaging in a total of 7 investment deals, with the most recent deal occurring on June 20, 2023. The latest funding round was a Series B, raising GBP 7.220 mn, led by Downing Ventures and accompanied by investments from Cambridge Innovation Capital and Guinness Global Investors. The current company valuation stands at GBP 25.705 mn. The founding team includes Paul McConkey and Tony Blake, with Charlie Horrell and David Wilkinson serving as current executives.ImageneVP offers a suite of advanced solutions primarily focused on genomics and biopharmaceutical development. Their core product offerings include a proprietary platform designed for the analysis and interpretation of genomic data, enabling pharmaceutical companies and research institutions to streamline drug discovery and development processes. This platform addresses critical challenges in personalized medicine by providing insights into genetic predispositions and therapeutic responses, thereby facilitating more effective treatment strategies. ImageneVP serves a diverse clientele that includes pharmaceutical companies, biotech firms, and academic research institutions across North America and Europe, specifically in major biotech hubs such as Boston, San Francisco, and London.In the most recent financial year, 2019, Imagen Ltd reported a revenue of GBP 3,164,516.10, with an EBITDA of GBP 0 for the year 2022. Revenue generation occurs through subscription-based models and strategic partnerships with key industry players, fostering B2B relationships that enable ongoing access to their genomic analysis platform and support services.In June 2023, Thomson Reuters Corporation announced plans to acquire Imagen Ltd, which will expand its agency business. This strategic move highlights Imagen's role in furthering research capabilities and enhancing product offerings. Moving forward, Imagen intends to leverage its recent funding to enhance its genomic analysis technology and expand into new markets, specifically targeting regions with burgeoning biotech sectors. The company aims to develop new products designed to advance genomic insights, although specific release dates have not been disclosed.

## Funding rounds

- Series B, Jan 3, 2019, $9.2M — Cambridge Innovation Capital, Downing, Guinness Global Investors
- Series A, Aug 22, 2016, $2.6M — Cambridge Innovation Capital
- Series A, May 29, 2015, $2.3M — Cambridge Innovation Capital
- Series A, May 28, 2014, $2.5M — Cambridge Innovation Capital

## Investors

- Cambridge Innovation Capital (https://capitalatlas.ai/funds/cambridge-innovation-capital) — Series A, Series B
- Downing (https://capitalatlas.ai/funds/downing) — Series B
- Guinness Global Investors (https://capitalatlas.ai/funds/guinness-global-investors) — Series B